SpectraScience, Inc. Receives Facility Approval From The FDA

SAN DIEGO, April 3 /PRNewswire-FirstCall/ -- SpectraScience, Inc. announced today that the U.S. Food and Drug Administration has given approval to the Company to manufacture its WavStat(TM) Optical Biopsy System in its Sorrento Valley facility.

Jim Hitchin the Company's CEO said, "This approval is the result of our submission of a PMA Supplement to our existing approved PMA. It allows us to manufacture and distribute the WavStat(TM) Optical Biopsy System from our San Diego facility."

The WavStat(TM) Optical Biopsy System is able to distinguish between normal, pre-cancerous, or cancerous tissue optically as compared to the current technique of physically removing suspected tissue and waiting for a pathology report. The System is currently approved by the FDA for use in detecting cancer in the colon. A new application for detecting pre-cancers in the throat, sometimes called Barrett's esophagus, is being tested in a clinical trial. Cancer of the esophagus is greater than 90% fatal and may develop as a result of chronic heartburn or GERD. Esophageal cancer is growing five times faster than all other cancers.

This news release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from the results discussed in the forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, the Form 10-KSB and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.

CONTACT: Jim Hitchin of SpectraScience, Inc., +1-858-847-0200

Web site: http://www.spectrascience.com/